On February 1, 2023, the Federal Trade Commission announced a complaint and stipulated order with GoodRx, with the FTC using for the first time its interpretation of the Health Breach Notification Rule. Under the Rule, the FTC interpreted a
“Forever and forever, farewell”: FTC prohibits indefinite retention of PHI in consent order
